What are the facts?
In 1982–1983, Technicolor, Inc. agreed to be acquired by an affiliate of MacAndrews & Forbes Group, controlled by Ronald Perelman, through a two-step transaction: a tender offer for a majority stake followed by a back-end cash-out merger for the remaining shares. Technicolor's board approved the deal after a compressed process and on the basis of an investment banker's fairness opinion delivered on short notice. Plaintiffs alleged the board failed to conduct a reasonable market check, failed to inform itself adequately about Technicolor's standalone value and potential alternatives, and allowed management to negotiate significant elements of the deal without sufficient board oversight. Cede & Co., a nominee holder for dissenting beneficial owners, pursued both an appraisal proceeding and a fiduciary duty action challenging the merger. After trial, the Court of Chancery applied the business judgment rule and ruled in favor of Technicolor's directors, reasoning in substance that in the absence of self-dealing or a controlling stockholder, entire fairness was not the operative standard. Cede appealed, arguing that the directors' grossly negligent process rebutted the BJR and required the defendants to prove the transaction's entire fairness. The litigation also implicated the company's DGCL §102(b)(7) exculpation provision, which the defendants asserted as a bar to monetary liability for due care violations.
What is the legal issue?
Does a plaintiff's showing that directors breached their fiduciary duty of care (by acting with gross negligence in approving a merger) rebut the business judgment rule and shift the burden to the directors to prove the transaction's entire fairness, even when there is no evidence of self-dealing or control by a conflicted stockholder; and how does DGCL §102(b)(7) affect liability and review?
What rule applies?
Under Delaware law, director decisions are presumed to have been made on an informed basis, in good faith, and in the honest belief that the action was in the best interests of the company (the business judgment rule). A plaintiff rebuts that presumption by showing that a majority of the board was either interested, lacked independence, acted in bad faith, or failed to inform itself of all material information reasonably available (gross negligence). Once the BJR is rebutted, the burden shifts to the defendants to demonstrate that the transaction was entirely fair to the corporation and its stockholders—measured by fair dealing (process, timing, initiation, structure, negotiations, approvals, and disclosures) and fair price (economic and financial considerations). Entire fairness is a unitary standard; both aspects must be shown, though they may be interrelated. DGCL §102(b)(7) permits corporations to include charter provisions exculpating directors from personal monetary liability for breaches of the duty of care, but it does not exculpate for breaches of the duty of loyalty, acts or omissions not in good faith, intentional misconduct, knowing violations of law, or transactions from which the director derived an improper personal benefit. Section 102(b)(7) does not alter the applicable standard of review or preclude equitable remedies.
What did the court hold?
Yes. Proof of a breach of fiduciary duty—such as grossly negligent decision-making that violates the duty of care—rebuts the business judgment rule and shifts the burden to the directors to prove the transaction's entire fairness, even absent self-dealing or control by a conflicted stockholder. The Court of Chancery erred by requiring evidence of self-dealing to trigger entire fairness. The case was remanded for an entire fairness determination, with consideration of any DGCL §102(b)(7) exculpatory protection regarding monetary liability for due care violations.
What is the reasoning?
The Supreme Court began by reaffirming that the BJR is a presumption of propriety grounded in director disinterestedness, independence, good faith, and due care. The presumption can be overcome by evidence that the board acted with gross negligence—i.e., failed to inform itself of all material information reasonably available—when approving a transaction. The record indicated substantial process deficiencies surrounding the board's approval of the two-step acquisition, including reliance on a hurried fairness opinion, minimal deliberation, limited exploration of alternatives, and significant delegation to management without adequate oversight. These alleged deficiencies, if proven, constitute a breach of the duty of care and suffice to rebut the BJR. The Court rejected the Chancery Court's view that entire fairness applies only when directors are self-dealing or a controlling shareholder stands on both sides. Rather, entire fairness becomes the operative standard of review once the BJR is rebutted for any reason—care, loyalty, or good faith—because at that point the usual deference to board decisions is unwarranted. With the presumption gone, the defendants bear the burden of proving the transaction was entirely fair in both process (fair dealing) and substance (fair price). The Court stressed that entire fairness is a single, flexible standard in which fair dealing and fair price are interrelated; strong evidence of fair price cannot fully cure an egregiously unfair process, though the two can inform each other. Turning to DGCL §102(b)(7), the Court explained that an exculpatory charter provision is an affirmative defense that, if applicable, can eliminate directors' personal monetary liability for duty-of-care breaches. However, §102(b)(7) does not insulate directors from equitable remedies (such as rescission or injunction), does not apply to non-exculpated claims (loyalty, bad faith, intentional misconduct, improper personal benefit), and does not restore the BJR once it has been rebutted. Thus, even where §102(b)(7) is present, courts may still apply entire fairness review and award appropriate equitable relief or damages against non-exculpated actors. Because the trial court's analysis rested on an incorrect legal premise regarding the trigger for entire fairness, the Supreme Court remanded for a proper entire fairness analysis and for consideration of any §102(b)(7) defenses to monetary liability.
Why is this case significant?
Cede clarifies the pathway from the business judgment rule to entire fairness and cements the burden-shifting framework used in fiduciary duty litigation. It teaches that a deficient process can have profound consequences: once plaintiffs show a breach that rebuts the BJR, defendants must affirmatively prove the transaction's fairness. The case also guides how §102(b)(7) operates—limiting monetary liability for care breaches without altering the applicable standard of review or precluding equitable remedies. For students, Cede is essential for understanding standards of review, director process obligations in mergers, the structure of proof and burdens, and the practical importance of exculpatory charter provisions.
Does Cede require evidence of self-dealing to trigger entire fairness review?
No. Cede holds that entire fairness applies once the business judgment rule is rebutted by any fiduciary breach—care, loyalty, or good faith. Self-dealing or control on both sides is one way to rebut the BJR, but not the only way. Grossly negligent process that violates the duty of care can suffice to shift the burden to defendants to prove entire fairness.
What does the entire fairness standard require directors to prove?
Directors must prove the transaction was entirely fair, showing both fair dealing and fair price. Fair dealing examines the process: initiation, timing, negotiation, structure, approvals, and disclosures. Fair price examines the substantive economic terms: market value, earnings, assets, future prospects, and comparable transactions. The two components are interrelated and assessed holistically.
How does DGCL §102(b)(7) affect cases like Cede?
An exculpatory charter provision adopted under §102(b)(7) can eliminate directors' personal monetary liability for duty-of-care breaches, but it does not protect against loyalty breaches, bad faith, intentional misconduct, or improper personal benefit. It also does not change the governing standard of review; courts may still apply entire fairness and grant equitable relief. Thus, §102(b)(7) narrows potential money damages without restoring deference or ending the case.
How does Cede relate to Smith v. Van Gorkom?
Like Van Gorkom, Cede underscores that inadequate information and rushed decision-making can constitute gross negligence and violate the duty of care. But Cede goes further in clarifying the consequence of a care breach: rebuttal of the BJR and a shift to entire fairness with the burden on directors. Cede also integrates the post–Van Gorkom statutory response—§102(b)(7)—by explaining its limits.
Is a market check required by Cede for every merger approval?
Cede does not impose a per se requirement of a market check, but it uses the adequacy of the process—including whether alternatives were reasonably explored—as evidence relevant to due care and to fair dealing. Where a sale of control is at issue, failure to reasonably canvass the market or otherwise ensure price maximization can help rebut the BJR and heighten the risk of entire fairness review.
What remedies remain available if §102(b)(7) exculpates directors for duty-of-care breaches?
Even if §102(b)(7) bars personal monetary liability for duty-of-care breaches, courts may grant equitable remedies (injunction, rescission, rescissory damages) and may impose monetary liability for non-exculpated claims (loyalty or bad faith). Liability may also attach to parties not covered by exculpation (e.g., aiding and abetting defendants or controllers), and the corporation itself can face equitable relief.